慢性阻塞性肺疾病急性加重期血清和肽素水平的变化及临床意义  

Changes of serum copeptin in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：井军虎[1] 李立宇[1] 李建强[2] 

机构地区：[1]天津市第四中心医院,天津300141 [2]山西医科大学第二医院

出　　处：《山东医药》2014年第37期19-20,23,共3页Shandong Medical Journal

基　　金：山西省自然科学基金资助项目(2013011055-3)

摘　　要：目的探讨慢性阻塞性肺疾病急性加重期(AECOPD)患者血清和肽素水平的变化及其临床意义。方法AECOPD患者90例,根据有无呼吸衰竭将患者分为无呼吸衰竭组43例、呼吸衰竭组47例,另取同期40例健康体检者为对照组。测定AECOPD患者治疗前后及对照组血清和肽素水平。结果治疗前呼吸衰竭组、无呼吸衰竭组血清和肽素分别为(25.31±16.33)、(10.34±4.37)pmol/L,均明显高于对照组(4.93±1.20)pmol/L(P均<0.01),且呼吸衰竭组明显高于无呼吸衰竭组(P<0.01)。治疗后呼吸衰竭组、无呼吸衰竭组血清和肽素分别为(5.93±3.37)、(5.47±1.60)pmol/L,均较治疗前显著降低(P均<0.01)。结论 AECOPD患者血清和肽素水平明显升高,有望成为AECOPD诊断及评价治疗效果的一个有用生物指标。Objective To explore the levels and clinical significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease（ AECOPD）. Methods 90 subjects with AECOPD were divided into on respiroatory faicure group（ n = 43）,respiratory failure group（ n = 47）,and forty healthy as a control group. The levels of serum copeptin of all AECOPD patients before and after treatment and control group were detected. Results Before treatment,the serum copeptin of the respiratory failure group was（ 25. 31 ± 16. 33） pmol /L,on respiroatory faicure group was（ 10. 34 ± 4. 37） pmol /L,all of them were higher than the control group（ 4. 93 ± 1. 20） pmol /L（ all P〈0. 01）,and the respiratory failure group was higher than the no respiratory failure group（ P〈0. 01）; after treatment,the serum copeptin of the respiratory failure group was（ 5. 93 ± 3. 37） pmol /L,on respiroatory faicur group was（ 5. 47 ± 1. 60） pmol /L,all of them were significantly reduced（ P〈0.01）. Conclusion The levels of serum copeptin is significantly increased in AECOPD patients. The serum copeptin is expected to be a useful biological index to estimate the AECOPD.

关 键 词：肺疾病 慢性 阻塞性 急性加重期 和肽素 

分 类 号：R563[医药卫生—呼吸系统]